



Company Profile

Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch's development stage product candidates include AC5 Advanced Wound System, AC5 Topical Hemostat, AC5-G and AC5 Surgical Hemostat.^{1, 2}

1. AC5-G and AC5 Surgical Hemostat are currently investigational devices limited by law to investigational use.
2. AC5 and associated logos are trademarks and/or registered trademarks of Arch Therapeutics, Inc. and/or its subsidiaries.

Management Team

Dr. Terrence W. Norchi

President, Chief Executive Officer and Director

Richard E. Davis

Chief Financial Officer

Recent News

Tuesday, January 05, 2021 - 07:55 AM

[Arch Therapeutics to Present at the H.C. Wainwright BioConnect Conference, January 11 - 14, 2021](#)

Monday, January 04, 2021 - 07:50 AM

[Arch Therapeutics Announces Distribution Agreement with Buffalo Supply, Inc.](#)

Friday, December 11, 2020 - 07:50 AM

[Arch Therapeutics to Present at the 13th Annual LD Micro Main Event Conference](#)

Tuesday, November 10, 2020 - 07:50 AM

[Arch Raises Approximately \\$1.1 Million with Convertible Note Issuance](#)

Monday, November 09, 2020 - 07:50 AM

Contact Information

Arch Therapeutics, Inc.

235 Walnut Street
Suite 6
Framingham, MA 01702

OTCQB: ARTH



Share Price	\$0.19
Volume	447.33k
Shares Outstanding	193,044,766
Market Cap	\$36.49m
52 Week High	\$0.26
52 Week Low	\$0.12

as of 01/25/2021

DISCLAIMER

Except for the historical information contained herein, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on Form 10-K and its quarterly reports on Form 10-Q. The Company does not undertake any obligation to update forward-looking statements. All trademarks and brand names are the property of their respective companies.